StockData
Seres Therapeutics, Inc. logo

Seres Therapeutics, Inc. (MCRB) stock

MCRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$1.41+0.00 (0.00%)

Close on Nov 17, 2026Market cap $14.02MP/E –Yield –

Seres Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Seres Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was -$80.59M. For fiscal 2025 it was -$89.84M. The highest annual figure on record is -$5.96M in fiscal 2013.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$89.84M–
FY2024Dec 31, 2024-$115.85M–
FY2023Dec 31, 2023-$188.85M–
FY2022Dec 31, 2022-$173.29M–
FY2021Dec 31, 2021-$58.55M–
FY2020Dec 31, 2020-$81.55M–
FY2019Dec 31, 2019-$64.27M–
FY2018Dec 31, 2018-$92.42M–
FY2017Dec 31, 2017-$84.14M–
FY2016Dec 31, 2016-$88.63M–
FY2015Dec 31, 2015-$54.13M–
FY2014Dec 31, 2014-$14.89M–
FY2013Dec 31, 2013-$5.96M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$20.60M–
Q1 FY2026Mar 31, 2026-$20.13M–
Q4 FY2025Dec 31, 2025-$18.42M–
Q3 FY2025Sep 30, 2025-$21.43M–
Q2 FY2025Jun 30, 2025-$23.82M–
Q1 FY2025Mar 31, 2025-$26.16M–
Q4 FY2024Dec 31, 2024-$27.75M–
Q3 FY2024Sep 30, 2024-$27.77M–
Q2 FY2024Jun 30, 2024-$27.45M-153.8%
Q1 FY2024Mar 31, 2024-$32.88M–
Q4 FY2023Dec 31, 2023-$35.39M–
Q3 FY2023Sep 30, 2023-$42.90M–
Q2 FY2023Jun 30, 2023$51.05M–
Q1 FY2023Mar 31, 2023-$69.17M–
Q4 FY2022Dec 31, 2022-$104.00K–
Q3 FY2022Sep 30, 2022-$57.36M-182.1%
Q2 FY2022Jun 30, 2022-$61.64M–
Q1 FY2022Mar 31, 2022-$54.18M–
Q4 FY2021Dec 31, 2021-$47.88M–
Q3 FY2021Sep 30, 2021$69.90M–
Q2 FY2021Jun 30, 2021-$46.72M–
Q1 FY2021Mar 31, 2021-$33.85M–
Q4 FY2020Dec 31, 2020-$16.39M–
Q3 FY2020Sep 30, 2020-$28.42M–
Q2 FY2020Jun 30, 2020-$18.85M–
Q1 FY2020Mar 31, 2020-$17.89M–
Q4 FY2019Dec 31, 2019-$17.39M–
Q3 FY2019Sep 30, 2019-$15.31M–
Q2 FY2019Jun 30, 2019-$9.03M–
Q1 FY2019Mar 31, 2019-$22.55M–
Q4 FY2018Dec 31, 2018-$19.68M–
Q3 FY2018Sep 30, 2018-$20.24M–
Q2 FY2018Jun 30, 2018-$26.18M–
Q1 FY2018Mar 31, 2018-$26.33M–
Q4 FY2017Dec 31, 2017-$27.87M–
Q3 FY2017Sep 30, 2017-$5.45M–
Q2 FY2017Jun 30, 2017-$26.66M–
Q1 FY2017Mar 31, 2017-$24.16M–
Q4 FY2016Dec 31, 2016-$23.99M–
Q3 FY2016Sep 30, 2016-$17.84M–

More Seres Therapeutics figures

See a number that looks wrong?